Seminars in Oncology
Volume 30, Issue 3 , Pages 361-368 , June 2003

Evidence-based follow-up of lung cancer patients

  • Thomas J. Smith

      Affiliations

    • Division of Hematology/Oncology, Department of Medicine and Massey Cancer Center; Williamson Institute of Health Economics, Department of Health Administration, Virginia Commonwealth University, Richmond, VA, USA
    • *Address reprint requests to Thomas J. Smith, MD, FACP, Division of Hematology/Oncology and Palliative Care, MCV PO Box 980230, 1101 E Marshall St, Richmond, VA 23298-0230 USA

References 

  1. Finucane T. How gravely ill becomes dying: A key to end of life care. JAMA. 1999;282:1670–1672
  2. American Society of Clinical Outcomes Working Group . Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol. 1996;14:671–679
  3. Cook DJ, Guyatt GH, Laupacis A, et al.  Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest. 1992;102:305S–311S
  4. Clinical Practice Guidelines for the Treatment of Unresectable Non-Small Cell Lung Cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol. 1997;15:2996–3018
  5. Gilbert S, Reid KR, Lam MY, et al.  Who should follow up lung cancer patients after operation?. Ann Thorac Surg. 2000;69:1696–1700
  6. Walsh GL, O’Connor M, Willis KM, et al.  Is follow-up of lung cancer patients after resection medically indicated and cost-effective?. Ann Thorac Surg. 1995;60:1563–1572
  7. Younes RN, Gross JL, Deheinzelin D. Follow-up in lung cancer: How often and for what purpose?. Chest. 1999;115:1494–1499
  8. Westeel V, Choma D, Clement F, et al.  Relevance of an intensive postoperation follow-up after surgery for non-small cell lung cancer. Ann Thorac Surg. 2000;70:1185–1190
  9. Mahadevia PJ, Fleisher LA, Frick KD, et al.  Lung cancer screening with helical computed tomography in older adult smokers: A decision and cost-effectiveness analysis. JAMA. 2003;289:313–322
  10. The AM, Hak T, Koeter G, et al.  Collusion in doctor-patient communication about imminent death: An ethnographic study. West J Med. 2001;174:247–253
  11. Emanuel EJ, Ash A, Yu W, et al.  Managed care, hospice use, site of death, and medical expenditures in the last year of life. Arch Intern Med. 2002;162:1722–1728
  12. Teno J, Lynn J, Wenger N, et al.  Advance directives for seriously ill hospitalized patients: effectiveness with the patient self-determination act and the SUPPORT intervention.SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment. J Am Geriatr Soc. 1997;45:500–507
  13. Rose JH, O’Toole EE, Dawson NV, et al.  Generalists and oncologists show similar care practices and outcomes for hospitalized late-stage cancer patients: SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks for Treatment. Med Care. 2000;38:1103–1118
  14. Weeks JC, Cook EF, O’Day SJ, et al.  Relationship between cancer patients’ predictions of prongnsis and their treatment preferences. JAMA. 1998;279:1709–1714
  15. Johnson FE, Naunheim KS, Coplin MA, et al.  Geographic variation in the conduct of patient surveillance after lung cancer surgery. J Clin Oncol. 1996;14:2940–2949
  16. Nauheim KS, Virgo KS, Coplin MA, et al.  Clinical surveillance testing after lung cancer operations. Ann Thorac Surg. 1995;60:1612–1616
  17. Mackillop WJ, Stewart WE, Ginsburg AD, et al.  Cancer patients’ perceptions of their disease and its treatment. Br J Cancer. 1988;58:355–358
  18. Loprinzi CL, Hayes D, Smith TJ. Doc, shouldn’t we be getting some tests?. J Clin Oncol. 2000;18:2345–2348
  19. Fossella F, DeVore R, Kerr R, et al.  Randomized phase III trial of Docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum containing chemotherapy regimens. J Clin Oncol. 2000;18:2354–2362
  20. Shepard FA, Dancey J, Ramlau R, et al.  Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095–2103
  21. Silvestri G, Pritchard R, Welch HG. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: Descriptive study based on scripted interviews. BMJ. 1998;317:771–775
  22. Fiset V, O’Connor AM, Evans W, et al.  Development and evaluation of a decision aid for patients with stage IV non-small cell lung cancer. Health Expect. 2000;3:125–136
  23. Davies E, Clarke C, Hopkins A. Malignant cerebral glioma—I: Survival, disability, and morbidity after radiotherapy. BMJ. 1996;313:1507–1512
  24. Davies E, Clarke C, Hopkins A. Malignant cerebral glioma—II: Perspectives of patients and relatives on the value of radiotherapy. BMJ. 1996;313:1512–1516
  25. Slevin ML, Stubbs L, Plant HJ, et al.  Attitudes to chemotherapy: Comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ. 1990;300:1458–1460
  26. Bremnes RM, Andersen K, Wist EA. Cancer patients, doctors and nurses vary in their willingness to undertake cancer chemotherapy. Eur J Cancer. 1995;31A:1917–1918
  27. Tamburini M, Buccheri G, Brunelli C, et al.  The difficult choice of chemotherapy in patients with unresectable non-small cell lung cancer. Support Care Cancer. 2000;8:223–228
  28. Balmer CE, Thomas P, Osborne RJ. Who wants second-line, palliative chemotherapy?. Psychooncology. 2001;10:410–418
  29. Frank A. At the Will of the Body. Boston, MA: Houghton Mifflin,; 1991;
  30. Lamont EB, Christakis NA. Prognostic disclosure to patients with cancer near the end of life. Ann Intern Med. 2001;134:1096–1105
  31. Christakis NA, Lamont EB. Extent and determinants of error in doctors’ prognoses in terminally ill patients: Prospective cohort study. BMJ. 2000;320:469–473
  32. GIVIO Investigators . Impact of follow-up testing on survival and health-related quality of life in breast cancer patients: A multicenter randomized controlled trial. JAMA. 1994;271:1587–1592
  33. Rosselli Del Turco MR, Palli D, et al.  Intensive diagnostic follow-up after treatment of primary breast cancer: A randomized trial. JAMA. 1994;271:1593–1597
  34. Nordic Gastrointestinal Tumor Adjuvant Therapy Group . Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: A randomized trial. J Clin Oncol. 1992;10:904–911
  35. Smith TJ, Swisher K. Telling the truth about terminal cancer. JAMA. 1998;279:1746–1748
  36. Smith TJ, Desch CE, Hackney MH, et al.  How long does it take to get a “do not resuscitate” order?. J Palliat Care. 1997;13:5–8
  37. Lamont EB, Siegler M. Paradoxes in cancer patients’ advance care planning. J Palliat Med. 2000;3:27–35
  38. Adlard JW, Joseph J, Brammer CV, et al.  Open access follow-up for lung cancer: Patient and staff satisfaction. J Clin Oncol. 2001;13:404–408
  39. Grunfeld E, Mant D, Yudkin P, et al.  Routine follow up of breast cancer in primary care: Randomised trial. BMJ. 1996;313:665–669
  40. Grunfeld E, Yudkin P, Adewuyl-Dalton R, et al.  Follow up in breast cancer: Quality of life unaffected by general practice follow up. Br Med J. 1995;311:54
  41. Grunfeld E, Fitzpatrick R, Mant D, et al.  Comparison of breast cancer patient satisfaction with follow-up in primary care versus specialist care: Results from a randomized controlled trial. Br J Gen Pract. 1999;49:705–710
  42. Grunfeld E, Gray A, Mant D, et al.  Follow-up of breast cancer in primary care vs specialist care: results of an economic evaluation. Br J Cancer. 1999;79:1227–1233
  43. Guillford T, Opomu M, Wilson E, et al.  Popularity of less frequent follow up for breast cancer in randomised study: Initial findings from the hotline study. Br Med J. 1997;314:174–177
  44. Mille D, Roy T, Carrere MO, et al.  Economic impact of harmonizing medical practices: Compliance with clinical practice guidelines in the follow-up of breast cancer in a French Comprehensive Cancer Center. J Clin Oncol. 2000;18:1718–1724
  45. Smith TJ, Heddinger S. Medically appropriate follow-up of breast and lung cancer patients. ASCO 2002 Educational Book. 2002;652–657

PII: S0093-7754(03)00148-9

Seminars in Oncology
Volume 30, Issue 3 , Pages 361-368 , June 2003

Article Tools